Regulatory Affairs – 第 2 頁

02 6 月 22

應對抗菌素耐藥性

The High-Level Steering Committee on Antimicrobial Resistance was set up in 2016 to call for collaboration, synergy and cross-fertilisation of all professional sectors under the "One Health" framework in response to AMR. Ms. Sabrina Chan, the Senior Executive Director of HKAPI has been a member of the Steering Committee since the establishment...

25 3 月 22

法規培訓課程系列完滿結束

14 1 月 22

Webinar – Introduction of the first Advanced Therapy Product GMP Facility in Hong Kong

Dr Daniel Lee of the Chinese University of Hong Kong, introduced the first ATP GMP facility in Hong Kong to our members.

14 1 月 21

粵港澳大灣區醫藥發展線上培訓課程2020

粵港澳大灣區發展是行政長官2020年度《施政報告》的一大重點。為幫助會員掌握發展機遇，香港科研製藥聯會在11月及12月與深圳醫院管理者協會合辦了有關粵港澳大灣區醫藥發展的線上培訓課程。

18 12 月 19

法規培訓課程：新藥註冊

約70名從事法規及藥物安全事務的會員，參與了本會於香港大學舉辦的新藥註冊法規培訓課程。

17 10 月 19

法規培訓：產品生命周期管理

約60名來自會員公司及學術界的來賓，參與了由香港大學及本會共同舉辦的產業生命周期管理法規培訓課程。（請參閱英文版本）

About 60 members, non-members and academics turned up for Product Life Cycle Management from Regulatory Perspective and Best Practice Workshop jointly organized by The University of Hong Kong and HKAPI.

14 12 月 18

藥物辦公室香港科研製藥聯會聯合通報會

衞生署藥物辦公室與本會於2018年12月14日舉行了聯合通報會議，逾90名業內會員參與其中。

09 1 月 18

Regulatory Training Programme Course 4 (Pharmacovigilance)

85 members, non-members and academics turned up for Regulatory Training Programme Course 4 – the last core course of the Programme which is jointly organized by The University of Hong Kong and HKAPI.

23 11 月 17

法規培訓課程第六課(臨床試驗)

The sixth course of the Regulatory Training Programme, that is jointly organized by the University of Hong Kong and HKAPI, was attended by 75 members and academics.

30 5 月 17

First Joint Forum in Macau (Regulatory Training Programme C5)

A forum on the current development and future of Macao’s pharmaceutical sector was recently held at the University of Macao (UM) Wu Yee Sun Library. The event was co-organised by UM’s Institute of Chinese Medical Sciences, the Pharmaceutical Society of Macao, and the University of Hong Kong (HKU) Li Ka...